Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon

A technology of replicators and antigens, which is applied in the direction of cancer antigen components, antibody medical components, virus antigen components, etc., and can solve problems such as easy contamination, trouble, and excessive length

Inactive Publication Date: 2016-12-14
US DEPT OF HEALTH & HUMAN SERVICES
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The process is cumbersome, lengthy, and prone to contamination during ex vivo steps

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
  • Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon
  • Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Example 1 - Generation of an alphavirus-based gene expression system

[0079] The alphavirus gene expression system is designed to allow VLP-mediated delivery of exogenous gene of interest (GOI) or protein of interest (POI) to target cells with low risk of causing cytopathic virus infection. An expression system was designed using three vectors that can be expressed in packaging cell lines to produce transduced VLPs. One vector encodes an alphavirus-based expression construct, another vector encodes a retroviral gag protein to facilitate VLP formation, and a third vector encodes a fusion protein to mediate fusion of VLPs to host cells. Additionally, the system is constructed to work without the presence of alphavirus structural proteins.

[0080] To achieve this, an alphavirus-based DNA plasmid was generated with the following: cytomegalovirus promoter (CMV); followed by a retroviral packaging signal for the corresponding retroviral packaging protein GAG; followed by a...

Embodiment 2

[0086] Example 2 - Expression of various proteins in target cells transduced with VEE VLPs

[0087] The basic concept of RNA delivery using VLPs is shown in figure 2 . In this experiment, a breast cancer model was used. A dual-promoter vector of the replicon was developed for the expression of HLA-DR1 and CD80 ( image 3 ). 4T1-Luc2 breast cancer cells were infected with VLPs encoding these two antigens. Using anti-HLA-DR and CD80 antibodies, it was shown that both proteins are indeed expressed in this cell. HLA-DR1 and CD80 have figure 2 Expression of the VLP-VEE replicon in VLP-transfected 4T1-Luc2 cells. Cells expressing HLA-DR1 were identified by using FITC-labeled anti-HLA-DR antibody. Cells expressing CD80 were identified by using PE-labeled anti-CD80 antibody.

[0088] To assess whether alphavirus replicons are capable of expressing two separate proteins in the same cell, VEE replication with HLA-DR1 under the control of one subgenomic promoter and CD80 under ...

Embodiment 3

[0089] Example 3 - Expression of various proteins in target cells transduced with VEE VLPs

[0090]To test VLPs in the mouse animal system, 4T1-Luc2 cells (highly aggressive and metastatic breast cancer cells) were implanted into the mammary fat pad of 10 mice. Tumors were visible within a few days and became apparent and palpable (5-7mm) within a week. Three mice were injected intratumorally with VLPs expressing inert protein (GFP), two mice were injected with VLPs expressing human HLA-DR1 / CD80 (allogeneic), and five mice remained uninjected as controls.

[0091] After 1 week, tumors were surgically removed from all mice and tumor regrowth and metastasis were followed over several weeks. result( Figure 5 ) showed that 4 out of 5 uninjected mice (untreated controls) died within 4-6 weeks due to cancer regrowth and metastasis in the lung, mammary gland and liver. All 3 mice injected with VLP / GFP (non-specific protein control) also died within 4-6 weeks due to cancer regrowt...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alphavirus structural protein gene.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Patent Application no. 61 / 916,394, filed December 16, 2013, under 35 U.S.C. § 119(e), the contents of which are hereby incorporated by reference in their entirety. field of invention [0003] The invention described herein relates to the delivery and transcription of class II major histocompatibility antigen-expressing nucleic acids to mammals using replication-defective virus-like particles. Background of the invention [0004] A major challenge in cancer therapy, especially chemotherapy, is the lack of specificity to target cancer cells, as small molecules are administered systemically and affect all cells with a high mitotic index, resulting in deleterious side effects. Antibody-based therapies exhibit improved specificity for target cells, but result in low efficacy. Monoclonal antibodies (mAbs) constitute one of the largest classes of reagents or drugs. The...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N7/04C12N7/01C12N15/86A61K39/12A61K39/00A61P35/00
CPCA61K39/0011A61K39/12C12N7/00C12N15/86A61K2039/5258A61K2039/53A61K2039/585C12N2740/11023C12N2770/36123C12N2770/36143C12N2770/36145C12N2800/24C12N2810/6081A61K39/001163A61K39/001191A61K39/001144A61K39/001124A61K39/001117A61K39/001181A61K39/001129A61K39/001182A61K39/001194A61K39/001152C12N2770/36134C12N2770/36152C12N2740/11042A61P35/00A61P43/00A61P31/12A61K45/06C12N2770/36171
Inventor D.K.查特吉S.J.卡茨玛茨克
Owner US DEPT OF HEALTH & HUMAN SERVICES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com